Real-World Data Shows Immunotherapy Benefits in HCC, But Liver Health Matters

Immunotherapy-based treatments are making a real difference for people with hepatocellular carcinoma‌ (HCC), the most common type of liver cancer. A recent study published ‍in JCO Global Oncology sheds light on how these‌ treatments perform in a real-world setting, confirming⁤ their effectiveness and safety while also highlighting the critical role of liver health in predicting outcomes.

Immunotherapy in HCC: ​A Real-World Perspective

This retrospective study, ⁣led by Dr. Leonardo Gomes da Fonseca⁤ from Oncology D’Or and institute​ of Research and teaching in Sao Paulo, Brazil,⁢ analyzed data from 148 patients with advanced ‌HCC treated with immunotherapy at 13 centers ‌in Brazil. The goal was to understand how these treatments perform outside the controlled environment of ⁢clinical trials. The study included patients treated with various ‌immunotherapy regimens, with a data cutoff of October 24, 2024.

Patient monitoring included regular radiologic assessments using Response Evaluation‌ Criteria in‍ Solid‌ Tumors v1.1 (RECIST) ​and tracking​ of adverse events using the National ‍Cancer Institute Common Terminology Criteria for⁢ Adverse Events v5.0.

Key findings: survival, Safety, and Predictors

The study revealed several important insights:

Overall survival: The median overall survival for the entire group was 14.7 months‌ (95%⁤ CI, 11.6-24.5), with 12- and 24-month survival‍ rates of 57.0% (95% CI,​ 47.7%-65.3%) and 41.4% (95% CI, 30.1%-51.5%), respectively. This demonstrates the potential for long-term survival benefits with ⁢immunotherapy in HCC.
Impact of Liver Function: Patients with better liver function, classified as Child-Pugh A and an Eastern cooperative Oncology Group (ECOG) ⁢performance status of 0-1 (n = 116), experienced a​ substantially ⁣longer median overall survival of 20.6 months (95% CI, ​12.4-25.8). This underscores the importance of baseline liver health in predicting treatment success.
Adverse Events: ​ Immune-related adverse events (irAEs) occurred in 19.6% of ‍patients, primarily involving thyroid disorders and ⁣skin issues. bevacizumab-related events, such as variceal and other ‍bleeding events, were also observed. The safety profile was generally consistent ⁢with what’s been seen in clinical trials.
Predictors​ of Worse Survival: The study identified three⁤ self-reliant predictors of worse survival:
Albumin-bilirubin grade 2 to 3 (HR, 2.87;​ 95% CI, 1.31-6.31; P = .008)
Metabolic dysfunction-associated steatotic liver disease (MASLD) ⁤(HR,⁢ 3.87; 95% CI, 1.37-0.94; P = .011)
Esophageal Varices (HR, 1.67; 95% CI, 1.39-1.90; P* = .005)

These findings emphasize the need to carefully assess liver function and pre-existing conditions before initiating immunotherapy in HCC patients.

The Importance of Liver Health in HCC ‍immunotherapy

These real-world results reinforce the idea that while immunotherapy offers hope⁤ for HCC patients, the condition of their liver plays a ⁣crucial role in determining how well they respond to treatment. Patients with more advanced liver disease or pre-existing⁤ conditions like MASLD and esophageal varices may not experience the⁣ same benefits as⁤ those with healthier livers.

Tailoring Treatment Strategies for HCC

“In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline ⁢variceal status,” the authors wrote. “These⁤ findings highlight the relevance⁤ of baseline liver disease characteristics ‍in guiding ‌immunotherapy in HCC and ​underscore the need for tailored management strategies.”

This means ⁢that doctors need to consider each‍ patient’s individual liver health when deciding if immunotherapy is the right choice and⁤ how to best manage their treatment. For example, patients​ with esophageal varices may need to be carefully monitored for bleeding risks, while those with MASLD may